Purchase this article with an account.
A.C. Liu, K. Narayana, S. Schwartzman, P. Latkany, C. Samson; Study in Outcomes of Sarcoid Uveitis Patients at a: Tertiary Referral Center . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2421.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine outcomes in patient with sarcoid–associated uveitis at an uveitis subspecialty clinic at an eye hospital.
Retrospective chart review based on the following factors: 1) control of inflammation at 6 months, 1 year, and 2 year follow up
2) comparison of Snellen Chart vision acuity at 6 months, 1 year, and 2 year from initial vision at treatment onset.
3) adverse outcomes to any treatment offered at NYEEI and necessity to convert to steroid sparing agents
1) Inflammation was uncontrolled in 100% of patients at initial visit, 67% at 6 months, 38% at 1 year, and 28% at 2 year. Control of inflammation was defined as less than 1+cell in the anterior chamber, no signs of intermediate or posterior involvement. Minor flare–ups of rare or trace cell in the anterior chamber (on or off treatment) were not considered to be uncontrolled inflammation. 2) Vision loss was 11% at 6 months, 16% at 1 year, and 6% at 2 years. The most common cause of worsening vision was glaucoma.
3) 40% of patients had adverse reactions to steroids. Of these patients, 85% of them required immunomodulatory therapy (IMT) to control their
inflammation. Of the patients on IMT, only 1 developed an adverse reaction (hypertension) which was controlled on medication.
Patients with sarcoidosis–associated uveitis experience a significantly high number of complications related to steroid use. Patients often require use of IMT, and benefited in terms of decreased vision loss and less medication–associated adverse reactions.
This PDF is available to Subscribers Only